Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Behavioral Intervention for Depression and Chronic Pain in Primary Care (Relief-Hybrid)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04290845
Recruitment Status : Not yet recruiting
First Posted : March 2, 2020
Last Update Posted : December 23, 2020
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:

Chronic pain and depression frequently co-exist in late and mid-life and contribute to increased disability, high health care costs, psychiatric comorbidity, and suicide. Older and middle-aged depressed-pain patients: a) are mainly treated in primary care practices; and b) are often prescribed medication, which increases the risk for addiction to opioids and benzodiazepines. Despite the need and desire by the patients and providers for primary care behavioral intervention, behavioral interventions are scarce in primary care.

To address this need, Relief-Hybrid was created. Subjects are randomized to either the Relief-Hybrid intervention or to Referral to Mental Health/Usual Care. Subjects in both arms will complete research assessments at 6, 9, and 12 weeks. Subjects in the Relief-Hybrid arm will receive 5 weekly sessions with the study therapist (licensed social workers, LCSWs) and 4 self-administered, mobile technology-assisted sessions.


Condition or disease Intervention/treatment Phase
Chronic Pain Depression Behavioral: Relief-Hybrid Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Research assistants will be blinded as to who is receiving Relief-Hybrid and who is receiving Usual Care.
Primary Purpose: Treatment
Official Title: Relief-Hybrid: A Behavioral Intervention for Depression and Chronic Pain in Primary Care
Estimated Study Start Date : May 2021
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chronic Pain

Arm Intervention/treatment
Experimental: Relief-Hybrid
Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
Behavioral: Relief-Hybrid
A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.

No Intervention: Referral to Mental Health/Usual Care
Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.



Primary Outcome Measures :
  1. Change in depression symptoms, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: Baseline, 6, 9, and 12 weeks ]
    The MADRS is a 10 item questionnaire assessing severity of depression by scoring participants on mood, anxiety, sleep, concentration, appetite, and suicidal thoughts. The lowest score is 0, no depression symptoms, and the highest possible score is 60, severe depression symptoms.

  2. Change in Pain-Related Disability, as measured by the Roland-Morris Disability Questionnaire (RMDQ) [ Time Frame: Baseline, 6, 9, and 12 weeks ]

    The RMDQ includes a scale assessing how much pain the participant has experienced in the past week, with 0 meaning no pain and 10 meaning pain as bad as he/she can imagine.

    The RMDQ also includes a series of questions related to pain disability, with 0 indicating no pain-related disability, and 24 indicating severe pain-related disability.


  3. Change in Mood, as measured by the Daily Photographic Affect Meter (PAM) [ Time Frame: Daily for 12 Weeks ]
    The PAM is used for assessing mood and emotional state. Participants can either score a "positive" or "negative" affect value.


Secondary Outcome Measures :
  1. Interoceptive Awareness, as measured by the Multidimensional Assessment of Interoceptive Awareness (MAIA) [ Time Frame: Baseline, 6, 9, and 12 weeks ]
    This assessment contains 32 questions measuring 8 areas of manifestations of emotions, including noticing, not-distracting, not-worrying, attention regulation, emotional awareness, self-regulation, body listening, and trusting. The scores for the questions associated with each of the 8 domains are averaged, with a score of 0 indicating "Never" and a score of 5 indicating "Always"

  2. Affect, as measured by the Positive and Negative Affect Schedule (PANAS). [ Time Frame: Baseline, 6, 9, and 12 weeks ]
    This scale consists of a series of 60 words and phrases and participants rate to what extent they have felt that way in the past week. The words are separated into 13 areas: general negative affect, fear, sadness, guilt, hostility, shyness, fatigue, general positive affect, joviality, self-assurance, attentiveness, serenity, and surprise. The scores range from 1 (very slightly/not at all), to 5 (extremely) for each word and each area is summed for the final score.

  3. Mood, as measured by the Mood Likert Scale [ Time Frame: Daily for 12 weeks ]
    This scale rates current sadness, ranging from 0 (not sad) to 10 (most sad). It also rates interest or pleasure in doing things, ranging from 0 (no interest or pleasure) to 10 (greatest interest or pleasure).

  4. Pain, as measured by the Pain Likert Scale [ Time Frame: Daily for 12 weeks ]
    This scale rates current pain, ranging from 0 (no pain) to 10 (worst pain possible).

  5. Stress, as measured by the Stress Likert Scale [ Time Frame: Daily for 12 weeks ]
    This scale rates current stress, ranging from 0 (no stress at all) to 10 (great stress).

  6. Activities Monitoring [ Time Frame: Daily for 12 Weeks ]
    Activities monitoring through a phone application; measuring distance covered daily by the participant during the week.

  7. Activities Monitoring [ Time Frame: Daily for 12 Weeks ]
    Activities monitoring through a phone application; measuring number of places visited daily during the week.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 50 years or older
  • PHQ-9 score greater or equal to 10
  • Chronic pain (non-cancer related, most days over the past 3 months)
  • Capacity to consent

Exclusion Criteria:

  • DSM-5 Axis 1 diagnoses other than depression and anxiety disorders
  • Montreal Cognitive Assessment (MoCA) < 24
  • Active suicidal ideation (MADRS item #10 greater or equal to 4
  • Severe or life-threatening medical illness
  • Patients on psychotropics, opioids or benzodiazepines will be included if they do not meet DSM-5 criteria for opioid, anxiolytics or other substance abuse disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04290845


Contacts
Layout table for location contacts
Contact: Dimitris Kiosses, PhD 914-997-4381 dkiosses@med.cornell.edu
Contact: Laurie Evans, MS 914-682-9100 ext 1012570 lad9011@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Internal Medical Associates (WCIMA)
New York, New York, United States, 10021
Contact: Joanna Pantelides    914-682-9100 ext 1012903    jop2285@med.cornell.edu   
Iris Cantor Men's and Women's Health Centers
New York, New York, United States, 10065
Irving Sherwood Wright Center
New York, New York, United States, 10075
Contact: Joanna Pantelides    914-682-9100 ext 1012903    jop2285@med.cornell.edu   
Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine
White Plains, New York, United States, 10605
Contact: Dimitris Kiosses, PhD    914-997-4381    dkiosses@med.cornell.edu   
Contact: Laurie Evans, MS    914-682-9100 ext 1012570    lad9011@med.cornell.edu   
Sponsors and Collaborators
Weill Medical College of Cornell University
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Dimitris Kiosses, PhD Weill Cornell Medicine
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT04290845    
Other Study ID Numbers: 19-10020967
5P50MH113838 ( U.S. NIH Grant/Contract )
First Posted: March 2, 2020    Key Record Dates
Last Update Posted: December 23, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified data from this study is submitted to the National Database for Clinical Trials related to Mental Illness (NDCT). The NDCT is run by NIH and allows researchers studying mental health to collect and share information with each other. Researchers must apply to NIH in order to be allowed access to the data for 1 year's time; after which they must re-apply.
Time Frame: Data will be available as per NIH's data sharing policy.
Access Criteria: Access criteria is determined by NIH and can be requested by applying online.
URL: https://nda.nih.gov/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weill Medical College of Cornell University:
Chronic Pain
Depression
Primary Care
Older Adults
Middle Aged
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Pain
Neurologic Manifestations